Seeking Alpha Author Darren McCammon joins Cheddar to discuss why investing in JCPenny's small bond $KTP may be more beneficial than investing in the company stock. He says that in order for the investment to be successful, JCPenney has to basically just stay afloat. It doesn't have to be doing well. And at this point, that may be a good thing, because the retailer's "reinvention" of itself isn't yielding the best results. McCammon says it's doing well in its electronics and appliances divisions, but lagging in women's clothing...which used to be the crux of the business. Plus, how does it stack up against Sears? McCammon says Sears' debt load is a much bigger problem than JCPenney's. He expects the troubled company to go bankrupt after the holiday season. This will benefit JCPenney, because Sears customers will move their money over.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More